19.10.2009 - 15:01
JERSEY CITY,N.J.----Lux Biosciences,Inc.,a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases,today announced that the company has closed a $50 million Series B venture financing.
Read full story on Yahoo
Ellre is a Research Service. Try our Fulltext Search top-right, or find a topic of your choice by using the above categories and be best informed.